#alef stock

[wealthyvc]

Aleafia Health Announces Results of Medical Cannabis Study Focused on Epileptic Patients - The Cannabis Investor

First of its Kind Study Written by Dr. Andrew Davis and Published in Peer-Reviewed “Journal of Drug Issues” 4000 Medical Cannabis Patient Study Leveraged Aleafia Health’s Proprietary Medical Cannabis Database TORONTO, March 18, 2019 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSXV: ALEF) (OTCQX: ALEAF) (FRA: ARAH) (“Aleafia Health” or the “Company”), announced the results of a 4,000 medical cannabis patient study (“The Study”) examining changes in employment and disability status among medical cannabis patients. The study was published on March 13, 2019 in the peer-reviewed Journal of Drug Issues, and is, to the Company and author’s knowledge, the first to ever directly observe physician-led medical cannabis usage and labour force status over time. SIGN-UP HERE to get the latest Aleafia Health press releases delivered to your inbox. The Study found a mild net improvement in employment after starting medical cannabis treatment, along with a reduction in unemployment and self-identified disability preventing employment. This is particularly notable as the vast majority of patients reported suffering from chronic illnesses, including pain, anxiety and depression, conditions which research indicates would ordinarily lead to a decrease in employment and labour force participation. Epileptic patients were the most likely to see improvements in their labour status. “These …

[wealthyvc]

Adapt or Die: Phase 2 of The Cannabis Boom Will Likely Be Led By Mergers and Acquisitions - The Cannabis Investor

News broke recently of a tie-up that shows the medical cannabis industry in a new light: it is a market where more mature players both gain opportunity and give it back to investors in high-potential smaller companies that could benefit from additional power. The merger hitting headlines sees Aleafia Health, Inc. (TSXV: ALEF) (OTCQX: ALEAF) pairing with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF). Aleafia announced in late December that it would acquire Emblem for a 27% premium over its share price at the time. More accurately, every share of Emblem is to be purchased with 0.8337 shares of Aleafia— meaning the more Aleafia’s share price climbs, the better the Emblem Shareholders do on the deal. Emblem makes cannabis capsules, oils, and sprays, which add value to Aleafia’s substantial end-to-end operations comprising everything licensed production of medical-grade cannabis and clinical operations. It’s a strong play by Aleafia and one that fits the company’s trend of making savvy moves to add to its own ability to deliver excellent products and services to customers and returns to investors. Aleafia Showed Emblem Investors a Brighter Future Aleafia has proven that they can create value with an acquisition strategy as they did with Canabo Medical …

Adapt or Die: Phase 2 of The Cannabis Boom Will Likely Be Led By Mergers and Acquisitions

The merger hitting headlines sees Aleafia Health, Inc. (TSXV: ALEF) (OTCQX: ALEAF) pairing with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF).